| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 4.500 +46.44% on 04/05/24 | | 10.000 -34.10% on 04/10/24 | +1.595 (+31.93%) since 03/25/24 |
| 3-Month | 4.000 +64.75% on 03/22/24 | | 10.000 -34.10% on 04/10/24 | +0.745 (+12.75%) since 01/25/24 |
| 52-Week | 4.000 +64.75% on 03/22/24 | | 13.980 -52.86% on 04/26/23 | -7.410 (-52.93%) since 04/25/23 |
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta to treat or prevent severe...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces it will...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first...
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2...
Synairgen plc (‘Synairgen’ or the ‘Company’)
Synairgen plc (‘Synairgen’ or the ‘Company’)
Press release
Press release
Press release
| 3rd Resistance Point | 7.543 |
| 2nd Resistance Point | 7.197 |
| 1st Resistance Point | 6.893 |
| Last Price | 6.590 |
| 1st Support Level | 6.243 |
| 2nd Support Level | 5.897 |
| 3rd Support Level | 5.593 |
| 52-Week High | 13.980 |
| Fibonacci 61.8% | 10.168 |
| Fibonacci 50% | 8.990 |
| Fibonacci 38.2% | 7.812 |
| Last Price | 6.590 |
| 52-Week Low | 4.000 |